Used in the treatment of autoimmune diseases such as systemic lupus erythematosus and IgA nephropathy by targeting and neutralizing APRIL (a proliferation-inducing ligand), this antibody helps reduce abnormal B-cell activation and the production of autoantibodies. It modulates the immune response, particularly in conditions where excessive APRIL contributes to chronic inflammation and tissue damage. Currently under clinical investigation, it shows promise in reducing disease activity and improving renal outcomes in patients with autoimmune kidney diseases.